Clinical Trial Update: A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ND0612 infusion as an adjunct to levodopa in Parkinson's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 (ND0612)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: WITHDRAWN